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1637ReplyMechanisms Affecting Platelet
Response to Antiplatelet Therapy
in Patients With ST-Segment
Elevation Myocardial InfarctionWe are grateful for the interest of Dr. Siasos and colleagues in the
results of our study (1). We acknowledge that all the factors able to
interact with platelet reactivity were not completely evaluated in our
study. In our assessment of the degree and speed of platelet inhi-
bition by prasugrel and ticagrelor loading doses in patients with
ST-segment elevation myocardial infarction (STEMI), we were
able to take into account the majority of clinical factors that may
inﬂuence on-treatment platelet reactivity. However, the analyses of
cellular and genetic factors were not the aim of our platelet function
test study. Genetic factors, especially regarding the cytochrome
P2C19*2 polymorphism, have been documented to affect the wide
variability in clopidogrel efﬁcacy (2). Clopidogrel variability
response has been associated with nonuniform drug absorption and
metabolism and strongly related with mid- and long-term
outcomes (3). On the other hand, prasugrel and ticagrelor do not
require such an extensive metabolism for starting their action and
are not supposed to be signiﬁcantly inﬂuenced by the genetic
variants that were studied in the clopidogrel era (4–6). Our data
suggest that drug absorption plays a major role in the speed of
action of the new oral antiplatelet agents in patients with STEMI.
In such patients, hemodynamic disarrangement, systemic vaso-
constriction, adrenergic activation, polypharmacotherapy (including
morphine use), abnormal muscular activity of the stomach and
intestines, and high risk of vomit may have a relevant role. We
cannot deﬁnitely exclude that still unknown polymorphisms may
inﬂuence prasugrel or ticagrelor gastrointestinal absorption.
However, despite the availability of user-friendly, point-of-care
genetic assays, able to provide results within 30 minutes, it is hard
to hypothesize that in the near future the antiplatelet agent load for
patients with STEMI undergoing emergent primary percutaneouscoronary intervention will be selected by genetic testing in the acute
phase.*Guido Parodi, MD, PhD
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